Table 2.
Risk of NPDR and STDR in patients with type 2 diabetes after propensity score matching.
| Metformin user events (total) | Metformin nonuser events (total) | Crude HR (95% CI) | Adjusted HR (95% CI) | |
|---|---|---|---|---|
| NPDR | 555/5022 | 578/5022 | 0.65 (0.58–0.73) | 0.76 (0.68–0.87) |
| STDR | 43/5022 | 68/5022 | 0.39 (0.27–0.58) | 0.29 (0.19–0.45) |
| STDR among NPDR patients∗ | 43/860 | 14/182 | 0.50 (0.27–0.92) | 0.54 (0.28–1.01) |
∗NPDR patients were those who received any oral antidiabetic drugs after the diagnosis of NPDR among the study population. NPDR: nonproliferative diabetic retinopathy; STDR: sight-threatening diabetic retinopathy; HR: hazard ratio.